CD79A and COVID-19: Our clinical data, along with assessments of humoral immune responses—including the detection of IgG, IgA, and IgM antibodies against the S and N proteins of SARS-CoV-2 and their corresponding neutralizing activity align with previously published results for both severe and mild/asymptomatic COVID-19 cases.